Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Boston Scientific, Guidant Close The Deal Following FTC Approval

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific closed its $28 bil. acquisition of Guidant on April 21, one day after the Federal Trade Commission approved the deal - the largest medical device acquisition in history

You may also be interested in...

Third Cardiovascular Giant Coming With $25 Bil. Abbott-St. Jude Deal

The previously rumored acquisition was announced on April 28, with the firms touting their extensive synergies in the cardiovascular space.

Boston Sci, J&J Bury The Hatchet In Guidant Acquisition Dispute

Boston Scientific will pay Johnson & Johnson $600 million to settle allegations that cardiovascular device firm Guidant breached a merger agreement with J&J in 2006, a far cry from the $7 billion sought by J&J

Abbott’s SPIRITs Are Raised By Positive Drug-Eluting Stent Data At ACC

Abbott's SPIRIT III trial for its Xience V everolimus-eluting stent bodes well for the device's market potential and points to a new direction for stent manufacturers' premarket relationship with FDA

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts